Macrogenics Inc(MGNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.23 | Insider Own | 3.54% | Shs Outstand | 63.6M | Perf Week | 6.39% |
| Market Cap | 0.15B | Forward P/E | - | EPS next Y | 6.89% | Insider Trans | -1.36% | Shs Float | 61.4M | Perf Month | -34.92% |
| Enterprise Value | 0.17B | PEG | - | EPS next Q | -0.32 | Inst Own | 79.4% | Short Float | 8.24% | Perf Quarter | -40.26% |
| Income | -0.01B | P/S | 0.89 | EPS this Y | -49.27% | Inst Trans | 10.2% | Short Ratio | 7.48 | Perf Half Y | -27.19% |
| Sales | 0.17B | P/B | 3.46 | EPS next 5Y | -20.19% | ROA | -35.12% | Short Interest | 5.06M | Perf YTD | 44.72% |
| Book/sh | 0.67 | P/C | 0.86 | EPS past 3/5Y | 15.37% 13.74% | ROE | -231.86% | 52W High | -54.13% ($5.08) | Perf Year | 40.36% |
| Cash/sh | 2.72 | P/FCF | - | Sales past 3/5Y | -0.54% 7.35% | ROIC | -6.18% | 52W Low | 80.62% ($1.29) | Perf 3Y | -54.4% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 59.94% | Gross Margin | 77.86% | Volatility(W/M) | 10.88% 10.9% | Perf 5Y | -88.62% |
| Dividend TTM | - | EV/Sales | 1.03 | Sales Y/Y TTM | 1.32% | Oper. Margin | -24.3% | ATR (14) | 0.29 | Perf 10Y | -89.28% |
| Dividend Ex-Date | - | Quick Ratio | 2.96 | EPS Q/Q | 153.45% | Profit Margin | -8.7% | RSI (14) | 30.77 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.96 | Sales Q/Q | 47.62% | SMA20 | -24.9% ($3.1) | Beta | 1.34 | Target Price | $8 |
| Payout | - | Debt/Eq | 4.62 | Earnings | 2026/8/13 | SMA50 | -36.23% ($3.65) | Rel Volume | 1.13 | Prev Close | $2.4 |
| Employees | 293 | LT Debt/Eq | 4.51 | EPS/Sales Surpr. | 497.95% -44.48% | SMA200 | -31.88% ($3.42) | Avg Volume(3M) | 0.68M | Price | $2.33 |
| IPO | 2013/10/10 | Option/Short | Yes/Yes | Trades | 4171 | Volume | 766,135 | Change | -2.92% |
🧬 A US clinical-stage biotech company developing antibody-based cancer therapeutics. Leveraging its proprietary bispecific and trispecific antibody technology platform, the company has built a pipeline of immuno-oncology drugs and antibody-drug conjugates, and is also advancing partnership programs with major pharmaceutical companies such as Gilead.
Over the past 1 year, roughly in the middle
54% below its 1-year high.
Traded about as much as usual. That is 113% of its average volume.
MGNX has a sound balance sheet but weak earning power
Of every $100 in sales, $24.30 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -49.3% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $89. Peers typically go for $946. Compared with its own 2-year average, it is 68% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -88.6%. The S&P 500 did +63% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 79.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #326 of 597 in the industry
Based on market cap of $148M.
FAQ
What kind of company is MGNX?
MGNX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MGNX?
The market cap of MGNX is approximately $148M, ranking 4,223 within its sector.
What is the 52-week high and low for MGNX?
MGNX has recorded a 52-week high of $5.08 and a low of $1.29.
